These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35367910)

  • 1. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
    Scherpereel A; Antonia S; Bautista Y; Grossi F; Kowalski D; Zalcman G; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Sun X; Lawrance R; Zhang X; Daumont MJ; Bennett B; McKenna M; Baas P
    Lung Cancer; 2022 May; 167():8-16. PubMed ID: 35367910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
    Reck M; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Cheng Y; Sakai H; Paz-Ares L; Lu S; John T; Sun X; Moisei A; Taylor F; Lawrance R; Zhang X; Sylvester J; Yuan Y; Blum SI; Penrod JR; Carbone DP
    Eur J Cancer; 2023 Apr; 183():174-187. PubMed ID: 36871487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
    Reck M; Schenker M; Lee KH; Provencio M; Nishio M; Lesniewski-Kmak K; Sangha R; Ahmed S; Raimbourg J; Feeney K; Corre R; Franke FA; Richardet E; Penrod JR; Yuan Y; Nathan FE; Bhagavatheeswaran P; DeRosa M; Taylor F; Lawrance R; Brahmer J
    Eur J Cancer; 2019 Jul; 116():137-147. PubMed ID: 31195357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1.
    Reck M; Ciuleanu TE; Lee JS; Schenker M; Audigier-Valette C; Zurawski B; Linardou H; Otterson GA; Salman P; Nishio M; de la Mora Jimenez E; Lesniewski-Kmak K; Albert I; Ahmed S; Syrigos K; Penrod JR; Yuan Y; Blum SI; Nathan FE; Sun X; Moreno-Koehler A; Taylor F; O'Byrne KJ
    J Thorac Oncol; 2021 Apr; 16(4):665-676. PubMed ID: 33485960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
    Reck M; Brahmer J; Bennett B; Taylor F; Penrod JR; DeRosa M; Dastani H; Spigel DR; Gralla RJ
    Eur J Cancer; 2018 Oct; 102():23-30. PubMed ID: 30103096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
    Peters S; Scherpereel A; Cornelissen R; Oulkhouir Y; Greillier L; Kaplan MA; Talbot T; Monnet I; Hiret S; Baas P; Nowak AK; Fujimoto N; Tsao AS; Mansfield AS; Popat S; Zhang X; Hu N; Balli D; Spires T; Zalcman G
    Ann Oncol; 2022 May; 33(5):488-499. PubMed ID: 35124183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
    Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ
    Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study.
    Reck M; Taylor F; Penrod JR; DeRosa M; Morrissey L; Dastani H; Orsini L; Gralla RJ
    J Thorac Oncol; 2018 Feb; 13(2):194-204. PubMed ID: 29129758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
    Cella D; Motzer RJ; Suarez C; Blum SI; Ejzykowicz F; Hamilton M; Wallace JF; Simsek B; Zhang J; Ivanescu C; Apolo AB; Choueiri TK
    Lancet Oncol; 2022 Feb; 23(2):292-303. PubMed ID: 35032437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
    Baas P; Scherpereel A; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Jahan T; Antonia S; Oulkhouir Y; Bautista Y; Cornelissen R; Greillier L; Grossi F; Kowalski D; Rodríguez-Cid J; Aanur P; Oukessou A; Baudelet C; Zalcman G
    Lancet; 2021 Jan; 397(10272):375-386. PubMed ID: 33485464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
    Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
    Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe.
    Moore A; Bennett B; Taylor-Stokes G; McDonald L; Daumont MJ
    BMC Cancer; 2022 Jun; 22(1):693. PubMed ID: 35739480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
    Moehler M; Xiao H; Blum SI; Elimova E; Cella D; Shitara K; Ajani JA; Janjigian YY; Garrido M; Shen L; Yamaguchi K; Liu T; Schenker M; Kowalyszyn R; Bragagnoli AC; Bruges R; Montesarchio V; Pazo-Cid R; Hunter S; Davenport E; Wang J; Kondo K; Li M; Wyrwicz L
    J Clin Oncol; 2023 Dec; 41(35):5388-5399. PubMed ID: 37713657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial.
    Bylicki O; Guisier F; Scherpereel A; Daniel C; Swalduz A; Grolleau E; Bernardi M; Hominal S; Prevost JB; Pamart G; Marques MH; Cloarec N; Deshayes S; Raimbourg J; Veillon R; Oulkhouir Y; Audigier Valette C; Subtil F; Chouaïd C; Greillier L;
    Lung Cancer; 2024 Aug; 194():107866. PubMed ID: 38972083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma.
    Wright K
    Oncology (Williston Park); 2020 Nov; 34(11):502-503. PubMed ID: 33206991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
    McNamee N; Harvey C; Gray L; Khoo T; Lingam L; Zhang B; Nindra U; Yip PY; Pal A; Clay T; Arulananda S; Itchins M; Pavlakis N; Kao S; Bowyer S; Chin V; Warburton L; Pires da Silva I; John T; Solomon B; Alexander M; Nagrial A
    J Thorac Oncol; 2024 Apr; 19(4):636-642. PubMed ID: 38036250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma.
    Ye ZM; Tang ZQ; Xu Z; Zhou Q; Li H
    Front Public Health; 2022; 10():947375. PubMed ID: 35937220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
    Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
    Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma.
    Dumoulin DW; Douma LH; Hofman MM; van der Noort V; Cornelissen R; de Gooijer CJ; Burgers JA; Aerts JGJV
    Lung Cancer; 2024 Jan; 187():107440. PubMed ID: 38104353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
    Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
    J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.